Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187875 | 0.98 | ALDH1A1 (0.55) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL4401738 | 0.89 | CA12 (0.53) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL3522931 | 0.88 | PAOX (0.59) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL8306310 | 0.88 | ALDH1A1 (0.53) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL16676932 | 0.85 | ALDH1A1 (0.54) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL21922782 | 0.84 | ACE2 (0.58) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL16078965 | 0.82 | ACE2 (0.56) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL13187886 | 0.82 | KDM4E (0.47) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL15806389 | 0.81 | KDM4E (0.48) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL8306450 | 0.80 | CARM1 (0.50) | ALDH1A1KDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016130968-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | YALE UNIVERSITY (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| EP-2705181-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Intellikine, LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| EP-1847532-B1 | IGF-1R INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-1847532-B1 | IGF-1R INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8338499-B2 | Amine co-initiators for radiation curable compositions | AGFA GRAPHICS NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-5561139-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0729471-A1 | SEMISYNTHETIC ANALOGS OF RAPAMYCIN (MACROLIDES) BEING IMMUNOMODULATORS | Abbott Laboratories (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5530120-A | ANALOGS OF ASCOMYCIN AND FK-506 AS IMMUNOSUPPRESSANTS AND-MODULATORS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| US-5527907-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| EP-0689545-A4 | MACROCYCLIC AMIDE AND UREA IMMUNOMODULATORS | ABBOTT LAB (US) | 1996-04-24 | — | — | EP | disclosed |
| EP-0689545-A1 | MACROCYCLIC AMIDE AND UREA IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1995014023-A1 | SEMISYNTHETIC ANALOGS OF RAPAMYCIN (MACROLIDES) BEING IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1994021634-A1 | SUBSTITUTED ALICYCLIC-ALIPHATIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994021642-A1 | MACROCYCLIC AMIDE AND UREA IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | ALDH1A1 2807/4885KDM4E 3453/4885CA12 1905/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | ALDH1A1 2932/4885KDM4E 3775/4885CA12 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.